Ancestim

Ancestim is a recombinant methionyl human stem cell factor, which has been commercialized under the brand name StemGen by Amgen. This therapeutic protein was developed with the intent of aiding in stem cell mobilization, particularly in the context of hematological malignancies and disorders where stem cell transplantation is a treatment avenue.

Production and Molecular Characteristics

Ancestim is synthesized using E. coli bacteria that have been genetically modified to express the human stem cell factor. Here's a deeper look into its molecular details:

• Protein Length: Ancestim is constructed of 166 amino acids, bestowing it a distinctive molecular structure.
• Molecular Weight: With a monomeric molecular weight of approximately 18,500 daltons, Ancestim in its physiological environment often assembles as a non-covalently associated dimer.
• Amino Acid Sequence: It reproduces the amino acid sequence expected from human DNA sequence analysis, barring the retention of an N-terminal methionine residue resulting from its expression in E. coli.
• Glycosylation: Being produced in E. coli, Ancestim is devoid of glycosylation, implying it doesn't contain the sugar moieties frequently found in proteins expressed in mammalian cells<ref>Apweiler, R., Hermjakob, H., & Sharon, N. (1999). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochimica et Biophysica Acta (BBA) - General Subjects, 1473(1), 4-8.</ref>.

Therapeutic Uses

Ancestim's application is rooted in oncology, specifically in the mobilization of peripheral hematopoietic stem cells—a procedure pivotal for patients diagnosed with cancers that are treated via stem cell transplantation:

• Formulation: Delivered as a sterile, white, lyophilized powder, Ancestim is free from preservatives. Post-reconstitution, it's primed for administration.
• Route of Administration: Once reconstituted, Ancestim is administered subcutaneously.
• Combination Therapy: Often, Ancestim is paired with filgrastim to boost the efficiency of stem cell mobilization<ref>Duarte, R. F., Shaw, B. E., Marín, P., Kottaridis, P., Ortiz, M., Morante, C., ... & Sureda, A. (2015). Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplantation, 50(6), 812-817.</ref>.

Conclusion

The development and deployment of Ancestim accentuate the marvels of genetic engineering in pioneering innovative therapeutics. Harnessing the potent protein expression system of E. coli to yield a crucial human stem cell factor, Ancestim stands as a testament to the progress of modern medicine. In the continually evolving field of oncology, agents like Ancestim, pivotal for stem cell mobilization and transplantation, undeniably hold significant importance.

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia